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ANALISIS PROTEOMIK PROTEIN PERKUMUHAN PEREMBES (ESP) 





Entamoeba histolytica ialah sejenis parasit protozoa yang menyebabkan 
amebiasis. Jangkitan parasit ini boleh menyebabkan disentri dan abses hepar yang 
mana jangkitan tersebut seringkali menyebabkan kematian jika tidak dirawat. Hingga 
kini, kefahaman patogenesis tentang jangkitan ameba adalah terhad. Oleh itu, dalam 
kajian ini, analisis proteomik dilakukan untuk mengenal pasti sub-proteom protein 
perkumuhan perembes dan protein membran dalam trofozoit E. histolytica. Dari 209 
protein, sebanyak 209 protein perkumuhan perembes telah dikenalpasti. Senarai ini 
masing-masing terdiri daripada 191 dan 97 protein yang berjaya dikesan oleh LC-
ESI-MS/MS dan LC-MALDI-TOF/TOF. Sebanyak 79 protein telah dikenalpasti oleh 
kedua-dua sistem spektrometri massa tersebut, manakala 112 dan 18 protein masing-
masing dikesan secara eksklusif oleh LC-ESI-MS/MS dan LC-MALDI-TOF/TOF. 
Ramalan in-silico mendapati 8 dan 31 protein masing-masing digolongkan sebagai 
protein perembes klasik dan tidak klasik. Klasifikasi ontologi menunjukkan 
peratusan besar iaitu sebanyak 23% protein perkumuhan perembes yang tergolong 
sebagai oxidoreductase. Seterusnya, fasa kedua kajian ini melibatkan perbandingan 
tiga kaedah pengekstrakan membrane iaitu dua kit komersil (ProteoExtract® daripada 
Calbiochem dan ProteoPrep® daripada Sigma), dan kaedah konvensional. Hasil 
kajian menunjukkan bahawa kit ProteoExtract® dan kaedah konvensional telah 
mengekstrak hasil protein yang lebih banyak berbanding dengan kit ProteoPrep®. 




mengenalpasti masing-masing protein sebanyak 490, 492, dan 587 daripada ekstrak 
membran yang menggunakan kit ProteoExtract®, ProteoPrep®, dan kaedah 
konvensional. Analisis in-siliko meramalkan protein membran sebanyak 109 (22%), 
237 (48%) dan 182 (31%) dalam ekstrak yang menggunakan kit ProteoExtract®, 
ProteoPrep® dan kaedah konvensional. Tambahan pula, pengenalpastian protein 
sitosol dan membran membuktikan bahawa kit ProteoPrep® merupakan kaedah yang 
paling selektif dan sensitif bagi pengekstrakan protein membran. Sebagai 
kesimpulan, hasil kajian ini telah membuktikan penemuan masing-masing 39 dan 
249 senarai protein perkumuhan perembes dan protein membran E. histolytica. 
Tambahan pula, kajian ini telah mengesahkan bahawa penggunaan dua jenis 
spektrometer massa boleh meningkatkan liputan proteom. Kajian ini juga telah 
menambahkan pemahaman tentang jenis protein yang dikumuh dan dirembes oleh E. 
histolytica dan juga protein yang berada di membran parasit tersebut. Protein yang 
dikenal pasti sangat berguna untuk kajian selanjutnya bagi memahami penyakit 






PROTEOMIC ANALYSES OF EXCRETORY SECRETORY PROTEINS 





Entamoeba histolytica is a protozoan parasite that causes amoebiasis. 
Infection of this parasite may lead to amoebic dysentery and amoebic liver abscess, 
which is fatal if left untreated. Until now, understanding of the pathogenesis of 
amoebiasis is limited. Hence, in this study, proteomic analyses were performed on 
the excretory-secretory (ES) and the membrane sub-proteomes of E. histolytica 
trophozoites. A total of 209 ES proteins were identified in which 191 and 97 proteins 
were detected by LC–ESI–MS/MS and LC–MALDI–TOF/TOF, respectively. Of the 
209 proteins, 79 were identified by both mass-spectrometry systems, while 112 and 
18 proteins were detected exclusively by LC–ESI–MS/MS and LC–MALDI–
TOF/TOF respectively. Subsequently, the secretome prediction analyses were 
performed whereby 8 and 31 out of 209 total proteins were identified as classically 
and non-classically secreted proteins, respectively. Functional annotation 
classification showed that the largest ES protein class, which is 23%, is the 
oxidoreductase. The second part of this study involved the comparison of three 
membrane protein extraction methods: two commercial kits (ProteoExtract® from 
Calbiochem and ProteoPrep® from Sigma), and a conventional laboratory method. 
The results showed that the ProteoExtract® kit and the conventional method extracted 
higher protein yields compared to the ProteoPrep® kit. The combined data from LC-
MALDI-TOF/TOF and LC-ESI-MS/MS identified 490, 492, and 587 proteins 




respectively. In-silico analysis predicted 109 (22%), 237 (48%) and 182 (31%) 
membrane proteins from the ProteoExtract®, ProteoPrep® and conventional method 
extracts, respectively. Furthermore, the identification of the cytosolic and membrane 
protein fractions showed that the ProteoPrep® extraction kit was the most selective 
and specific for the extraction of the membrane proteins. In conclusion, the results 
revealed 39 and 249 E. histolytica ES and membrane proteins, respectively. 
Furthermore, this study confirmed that the use of two types of mass spectrometers 
enhances proteome coverage. The data generated has increased the understanding on 
the types of proteins that are excreted-secreted by E. histolytica and also the proteins 
that reside at the parasite’s membrane. The identified proteins will be useful for 
further studies in understanding the pathogenesis of amoebiasis and the roles the 






CHAPTER 1 ‒ INTRODUCTION 
 
1.1 An overview 
Amoebiasis was first reported as a deadly disease in 1873 by Hippocrates who 
examined a patient suffering from bloody dysentery (Tanyuksel and Petri, 2003). 
Two years later, Entamoeba histolytica trophozoite was identified by Fedor 
Aleksondrovich Lösch in a farmer who suffered from a fatal case of dysentery 
(Marshall et al., 1997). Further investigation by inoculating the stool of the patient 
into the rectum of a dog caused a similar manifestation (Marshall et al., 1997). A 
significant milestone was achieved with the characterisation of E. histolytica as the 
causative agent for amoebic colitis and amoebic liver abscess (ALA) in the 1890s by 
Sir William Olser and his colleagues (Tanyuksel and Petri, 2003). Subsequently, the 
identification of cyst as an infectious stage was confirmed by Walker and Sellards in 
1913, and followed by the establishment of the E. histolytica life cycle by Dobell in 
1925 (Tanyuksel and Petri, 2003).  
Most patients infected with E. histolytica are asymptomatic or only suffered 
from mild diarrhoea (Hankenson et al., 2003). Meanwhile, only 10% of the patients 
presented classic amoebic symptoms such as stomach cramps and bloody diarrhoea 
(Farthing, 2006). E. histolytica was not immediately associated as the causative agent 
of amoebiasis because most amoebic infections cases were asymptomatic. However, 
subsequent studies found that the infectious and the non-infectious amoeba were not 
similar (Fotedar et al., 2007). Since then, E. histolytica was reclassified into two 
species namely the infectious species, E. histolytica and the non-infectious species, 




In 1997, amoebiasis was ranked second as death-causing parasitic infection, 
after malaria (World Health Organization, 1997). Approximately 40, 000 to 100, 000 
deaths occurred annually, which include 1.9% to 9% of amoebic colitis patients 
(Aristizábal et al., 1991). Death occurrence in amoebic liver abscess (ALA) cases 
have decreased to 1 – 3% due to the effective medical intervention. Nonetheless, the 
mortality rate caused by the late detection resulting in the sudden intraperitoneal 
rupture occurred in 2 – 7% of the patients (Stanley Jr, 2003). 
The results of previous studies have contributed to the advancement on many 
aspects in the management of amoebiasis. This includes a better way of diagnosis 
whereby the detection of pathogenic E. histolytica could be accurately distinguished 
from the morphologically similar but non-pathogenic E. dispar (Fotedar et al., 2007). 
Although many attempts have been made to improve the management of amoebiasis, 
the disease remains prevalent in underdeveloped countries of warmer climate (Walsh 
and Ravdin, 1988). Furthermore, the combination of poor sanitation and bad water 
quality provides the optimum breeding ground for this parasite (Walsh and Ravdin, 
1988).  
Large amounts of information on E. histolytica genome were made available 
since it was sequenced in the year 2005 (Loftus et al., 2005). In tandem, the advent 
of proteomic technologies has allowed proteomic studies on amoebiasis to be 
conducted. Early studies focused on analysing the subcellular expression profiles of 
trophozoites under various conditions (Davis et al., 2006, Tolstrup et al., 2007, 
Perdomo et al., 2015). Tolstrup et al. (2007) used 2-dimensional gel electrophoresis 
(2-DE) followed by mass spectrometry (MS) on 400–1500 E. histolytica protein 
spots. Therein, 63 proteins were identified and found related to cytoskeleton, surface, 




application of differential protein expression analysis using 2-DE and subsequent MS 
analysis was also performed to compare the proteome of Rahman and HM1:IMSS 
strains of E. histolytica. The results showed six proteins were found differentially 
expressed between the two strains (Davis et al., 2006). In 2015, a study on the E. 
histolytica trophozoite ER and Golgi apparatus using LC-MS/MS identified over 
1,500 proteins of which are involved as trafficking machinery and GTPases 
(Perdomo et al., 2015). Hence, with the advancement of proteomic technologies and 
a complete E. histolytica protein database, high-throughput studies on the proteome 
of E. histolytica can be conducted. 
 
1.2 Problem statements and rationale of the study 
The shift of analysing a single protein to larger sets of proteins such as the excretory-
secretory (ES) proteins and membrane proteins is made possible with advances in the 
proteomics technologies. Currently, there is no proteome report on the ES proteins of 
E. histolytica. Other than the study of E. histolytica cell surface membrane proteins 
by Biller et al. (2014), no other study has been performed on the membrane proteome 
of E. histolytica. Thus, this study aimed to identify the ES and membrane proteomes 
of E. histolytica. The identification of these proteins and their functions could add to 




1.3 Objectives of the study 
This study was conducted with the following objectives: 
1. To perform proteomic analysis using LC-MALDI-TOF/TOF and LC-ESI-
MS/MS and functional classification via PANTHERDB for the identified E. 
histolytica excretory-secretory proteins. 
2. To compare E. histolytica membrane protein extraction methods: two 
commercial kits namely ProteoExtract® (Calbiochem), ProteoPrep® (Sigma), and 
a conventional laboratory method. 
3. To perform proteomic analysis using LC-MALDI-TOF/TOF and LC-ESI-
MS/MS and functional classification via PANTHERDB for the identified E. 














CHAPTER 2 ‒ LITERATURE REVIEW 
2.1 Biology of E. histolytica 
2.1.1 Life cycle 
E. histolytica exists in two distinct stages namely trophozoites and cysts. The simple 
life cycle begins with the consumption of the tainted fluid containing E. histolytica 
cyst (Hankenson et al., 2003). The cyst withstands harsh environment such as the 
gastric acid. Upon reaching a conducive environment such as the small intestine, a 
single cyst ex-cysts to form 8 trophozoites. These blood ingesting trophozoites then 
colonise the colon and cause dysentery. Trophozoites are unable to live in an 
unconducive environment outside the host or the host’s gastric acids unless 
quadrinucleate cysts are formed again through a process known as encystation. 
Humans and primates are the only natural hosts for E. histolytica (Rivera et al., 2010, 














2.1.2 Cell morphology 
E. histolytica is a unicellular eukaryotic organism. The cyst form of E. histolytica is 
round in shape and is enclosed within a refractile wall which protects them from 
harsh conditions such as the stomach acid. It is responsible for the transmission of 
the disease. A mature cyst is 10-15 μm in size and consists of four nuclei. From a 
single quadrinucleate cyst, eight uninuclear trophozoites are formed through a 
process known as excystation. The trophozoite form of E. histolytica is 10-50 μm in 
size and consists of one nucleus. It is actively motile with finger-shaped pseudopodia 
and responsible for tissue invasion and damage. It is also responsible for causing 
tissue damage to the host (Stanley Jr, 2003). 
In the trophozoite form, it contains a single nucleus and multiplies by binary 
fission. It is an endoparasite whereby it ingests nutrients from the host and can alter 
its shape for various purposes such as locomotion and evasion of the host immune 
responses (Espinosa-Cantellano et al., 1992, Markiewicz et al., 2011). 
Other amoeba species such as E. dispar and E. moshkovskii share the same 
physical features with E. histolytica, thus causing difficulty in differentiating them 
from E. histolytica under the microscope (World Health Organization, 1997, Fotedar 
et al., 2007). The need to distinguish E. histolytica from other non-pathogenic 




2.1.3 Transmission and occurrence 
2.1.3(a) Susceptibility and risk factors 
Typically, amoebiasis is acquired through the faecal-oral route, whereby food or 
water contaminated by the cyst form of E. histolytica is ingested by the host. 
Transmission can also occur through oral and anal sex as well as contaminated 
enema apparatus (Istre et al., 1982). According to Hankenson et al. (2003), the 
communicability of the disease is high as asymptomatic carriers can be a source of 
further infection. Furthermore, common household pest like flies and cockroaches 
can help spread the cyst form of E. histolytica. Adults and infants have similar 
chances of acquiring amoebiasis. However, according to a report by Hung, Chang & 
Ji (2012), men who have sex with men have a higher risk of being infected with E. 
histolytica. 
Amoebiasis is still a major health problem especially among the aboriginals 
and communities living in the remote areas of Malaysia (Tengku and Norhayati, 
2011). A study on the prevalence of E. dispar/E. histolytica among school children in 
the interior of Sabah showed that 83.8% of them had the infection (Mahsol et al., 
2008). One of the leading factors causing high intestinal parasitic infections 
including E. histolytica in remote communities involves water sources (Duc et al., 
2011). For instance, the transmission of parasites occurs in settings where a river 
contaminated with human and animal excretion is used interchangeably for 







Amoebiasis commonly occurs in populations living in tropical areas that lack proper 
sanitation. The disease is prevalent in developing countries such as Mexico, India, 
Africa and Malaysia (Centers for Disease Control and Prevention, 2015). In western 
Nepal, amoebic infection was ranked second after giardiasis (Mukhopadhyay et al., 
2007). The prevalence of E. histolytica infection in the different regions of Brazil 
from the year 2001 to 2014 ranged between 6.8% and 46.3% (Silva et al., 2014). In 
Pakistan, the prevalence of E. histolytica was reported to be as high as 23.1%, 
whereby the most susceptible age group was found between 6 to 10 years old (Zeb et 
al., 2018). 
In Malaysia, the prevalence of amoebiasis among the Orang Asli was found 
between 1% and 14% (Norhayati et al., 2003) (Figure 2.2). An outbreak of 
amoebiasis among the orang asli communities in the year 2004 reported 13.2% of 28 
diarrhoea patients were infected by E. histolytica (Noor Azian et al., 2006). In 2005, 
72.4% out of 58 liver abscess patients admitted to Hospital Universiti Sains Malaysia 
(HUSM) were found to be caused by E. histolytica (Zeehaida et al., 2008). 
Furthermore, between 2008 and 2009, 76.7% out of 30 liver abscess cases admitted 
to HUSM were also positive for E. histolytica DNA (Othman et al., 2010).  
Despite being prevalent in tropical countries, human to human transmission 
can still occur regardless of climate and high sanitation standards. For example, in a 
temperate country such as Japan, mass E. histolytica infection at an institution for the 
mentally disabled in the Yamagata Prefecture of Japan reported 5 to 10% of people 
infected were symptomatic, while 90 to 95% of infected subjects were asymptomatic 




the Netherlands demonstrated that E. histolytica can remain dormant for 13 years in 
their climate. 
 
2.1.4 Disease, diagnosis and treatment 
2.1.4(a) Symptoms 
In most E. histolytica infections, symptoms are either not present or very mild 
(Stanley Jr, 2003). The majority of asymptomatic patients excrete cysts for a short 
period and are clear from the infection within 12 months of infection (van Hal et al., 
2007). Only a small percentage of people infected with E. histolytica develops 
clinical symptoms. Patients with symptomatic amoebiasis often suffer from amoebic 
colitis and amoebic liver abscess (ALA) (Stanley Jr, 2003). 
Patients with amoebic colitis commonly present a history of persistent 
abdominal pain and diarrhoea with the presence of blood and mucus in the stool. As 
amoebiasis is often neglected, a study reports that common inappropriate 
symptomatic treatment using corticosteroid has led to toxic megacolon complication 
in about 0.5% of patients (Ackers et al., 1997). Furthermore, when left untreated, the 
resulting gut perforation, exhaustion, and extraintestinal amoebiasis will lead to 
death (Hankenson et al., 2003). 
ALA is the most common extraintestinal manifestation of amoebiasis (van 
Hal et al., 2007). As mentioned by Zurauskas & McBride (2001), patients who 
develop ALA are usually presented within 5 months of exposure to the disease, with 
clinical symptoms such as fever, and right upper abdominal quadrant pain. The 
majority of ALA patients do not present amoebic colitis symptoms and also E. 


















Figure 2.2 A compilation of studies by Norhayati et al. (2003) on the prevalence 






The earliest diagnosis method of amoebiasis is the microscopic examination of stool 
samples whereby E. histolytica trophozoites can be seen containing red blood cells. 
However, this method is prone to cause misdiagnosis as other morphological similar 
strains, such as. E. dispar and E. moshkovskii are indistinguishable from E. 
histolytica under the microscope (Liang et al., 2009, Haque and Petri, 2006). 
Although microscopic method is routinely being used to diagnose amoebic colitis, it 
is not suitable to be performed for diagnosis of ALA cases. Despite low sensitivity of 
the microscopy, it is still being practised in many hospital laboratories.  
Amoebic colitis patients can also be diagnosed by detecting small ulcers on 
colonic lesions obtained during the colonoscopic biopsy (Ohnishi et al., 2004). 
Furthermore, colonoscopy and subsequent sampling by means of culture swap are 
useful in patients with acute colitis and in cases when E. histolytica infection is 
suspected but failed to be detected in stool samples. However, these methods are 
time-consuming and sensitivity of the diagnosis is only 50% (Clark and Diamond, 
2002). Antigen detection methods, eg. Entamoeba CELISA Path kit (Cellabs, 
Sydney, NSW) and the E. histolytica II kit (TechLab Inc, Blacksburg, Va, USA), are 
specific and can distinguish E. histolytica from E. dispar. The sensitivities and 
specificities of these various antigen detection kit ranges from 80% to 99% and from 
86% to 98%, respectively (Haque et al., 1995, Gonin and Trudel, 2003, Furrows et 
al., 2004, Solaymani-Mohammadi et al., 2006). These tests are rapid and their 
interpretations are more definitive compared to the microscopic examination. 
For the diagnosis of extraintestinal amoebiasis such as ALA, radiology 




present, further analyses such as culture, DNA detection, and/or antigen detection are 
performed. DNA and antigen detection-based methods performed on the abscess 
sample were reported to be highly sensitive (Fotedar et al., 2007, Paul et al., 2007, 
Tanyuksel and Petri, 2003). With serological methods, serum samples were used to 
detect antibodies against E. histolytica for the diagnosis of ALA. Commercial 
antibody detection assays made of native E. histolytica trophozoite antigens are 
available (Lotter et al., 1992, Ning et al., 2013). However, this method is ineffective 
to distinguish recent infection from past infection as high background antibody titre 
may persist in a population of endemic areas (Pillai et al., 1999, Zengzhu et al., 1999, 
Zeehaida et al., 2008, Mohamed et al., 2009). 
Molecular diagnostic tests using polymerase chain reaction (PCR) to amplify 
E. histolytica DNA from the extracted faecal and pus of ALA patients are shown to 
be highly sensitive and specific (Gonin and Trudel, 2003, Solaymani-Mohammadi et 
al., 2006). Furthermore, the application of real-time PCR (RT-PCR) has significantly 
shortened detection time by simultaneous monitoring of the amplification process 
(Othman et al., 2010). The advantages of RT-PCR are the ability to detect a low 
number of parasite and the reliability in differentiating non-pathogenic Entamoeba 
species from E. histolytica (van Hal et al., 2007). However, these methods require 
skilled personnel and the high cost of reagents and equipment.  
 
2.1.4(c) Treatments 
Treatment for amoebiasis includes the oral administration of metronidazole or 
diiodohydroxyquin and in conjunction with a luminal agent such as iodoquinol 




may be unnecessary to treat ALA, as drug therapy alone is efficient (Akgun et al., 
1999). However, aspiration of the abscess was shown to be beneficial in patients with 
large abscesses (Weinke et al., 2002). Meanwhile, asymptomatic carriers should be 
treated with a luminal agent to reduce the spread of disease and the risk of 
developing  symptomatic infection (Stanley Jr, 2003). 
Current drug therapies have been shown to cause several side effects. 
According to Petri Jr & Singh (1999), effective luminal agents such as diloxanide 
furoate and paromomycin caused frequent gastrointestinal disturbances and rare 
double vision, and symptoms related to ototoxicity and nephrotoxicity. Furthermore, 
other drugs used to treat amoebiasis such as metronidazole may cause unpleasant 
side effects, such as metallic taste, nausea and headache. Although it is uncommon, 
metronidazole can also cause neurological side effects, such as vertigo and 




According to Lejeune, Rybicka, & Chadee (2009), E. histolytica trophozoites can 
maintain a commensal relationship with the host. This is generally observed in the 
infected individuals. When triggered, the unharmful relationship can turn destructive, 
beginning from the destruction of the intestinal wall, to the extent of invading 
surrounding soft organs such as the liver. Several works have been performed to 
distinguish the virulent and attenuated strains as well as to uncover the stress-
inducing components from the tissue environment (Faust and Guillen, 2012). 




needs to be further elucidated. The current knowledge of the pathogenesis of 
intestinal amoebiasis is shown in Figure 2.3. 
This host tissue lysing parasite has phagocytic, proteolytic, and cytolytic 
capabilities. Gal-lectin, cysteine proteinase and amoebapore are the three proteins 
known as the main culprit in the pathogenesis of amoebiasis. The invasion of the 
intestinal mucosa by the degradation of the mucin layer is thought to be the first 
strategy to disrupt the mucus gel (Moncada et al., 2005). In this strategy, the cysteine 
proteases secreted by E. histolytica effectively degraded the cysteine-rich domains of 
the MUC2 polymer of the mucus gel. Hence, it permits the parasite to come into 
contact with the epithelial surface (Lidell et al., 2006). 
Then, the trophozoites attach to the tissue surface through its surface protein, 
namely Gal/GalNAc lectin. This leads to the cytolysis of the host cell (Tavares et al., 
2005). A more recent study using an ex-vivo human intestinal model to study E. 
histolytica pathogenesis found that impairing the Gal/GalNAc lectin did not inhibit 
the parasite’s attachment ability (Bansal et al., 2009). This study suggests that other 
molecules may also be involved in the adherence process. Subsequently, the 
destruction of the villin and microvilli occur as the trophozoites continue to secrete 
cysteine proteases.  
The prevention of E. histolytica from invading the sub-epithelium region 
involves the production of nitric oxide (NO) and reactive oxygen species (ROS) in 
the activated macrophages. However, the parasite is able to defend itself from the 
attack by neutralising both NO and ROS with peroxiredoxin (Choi et al., 2005). 
Various proteins are involved in progressing intestinal amoebiasis to 




establishment of amoebic liver abscess (ALA) (Zhang et al., 2004). In addition, 
according to Santi‐Rocca et al. (2008), the parasite upregulates the expression of 
lysine and glutamic acid-rich protein (KERP1) during ALA formation. The roles of 
these proteins are postulated in the protection of this parasite from an acute immune 










2.2 The proteome of E. histolytica 
The term proteome was coined by Marc Wilkins in 1994 and it was defined as an 
entire complement of proteins expressed by the genome, cell, tissue or the entire 
organism (Wilkins et al., 2013). The overall aim of proteome studies is to perform 
large-scale discovery of the proteome by analysing many proteins at the same time. 
Large-scale proteomics approach, also known as a bottom-up strategy, has been 
proven to be an indispensable tool towards understanding the parasite pathogenesis 
(Veras and Bezerra de Menezes, 2016, Bertin et al., 2016). 
For pathogens such as E. histolytica, its proteome is important for the 
pathogenicity of the disease and the cell viability. In amoebiasis, E. histolytica 
evades the immune system using surface receptor capping on the uropods. In this 
event, the targeted host immune components on the parasite’s surface are 
translocated and shed at the uropod (Avila-Calderón et al., Espinosa-Cantellano et 
al., 1992, Markiewicz et al., 2011). The shedding of uropods from the parasite 
suggests that the isolated fraction contains various molecules at the plasma 
membrane. The uropod shedding also suggests its involvement in the excretory 
mechanism of the trophozoites. In a study to understand the mechanism of uropod 
formation, the identification of the uropod proteome showed several numbers of 
multiple drug resistance proteins, ATPases, GTPases, and cysteine proteases 
(Markiewicz et al., 2011).  
The E. histolytica proteome plays an important role in the encystation and 
excystation in response to the environment. Proteome analysis of the total E. 
histolytica protein identified 1029 proteins from the trophozoite form, 550 proteins 




proteins found to be common across all the three forms (Luna-Nácar et al., 2016). 
This study suggests that CLS may be an intermediate survival strategy of 
trophozoites towards stressful condition, of which the process enables the parasite to 
form a chitin-like resistant cover containing Jacob protein as a shelter.  
During host infection, E. histolytica is exposed to reactive oxygen species 
that are released by the host’s immune cells at the site of the infection. Shahi et al. 
(2016) identified 154 oxidising proteins, in which these proteins were involved in 
transport, catalysis, antioxidant activity, and maintaining the parasite's cytoskeleton. 
They also reported the involvement of arginase in the protection of the parasite 
against oxidative stress that was induced by the host. These results emphasise the 
contribution of oxidative stress by the host cells to the pathogenesis of E. histolytica.  
Proteome analysis aimed to elucidate the migration-related proteins have 
identified EhPC4 (positive coactivator 4) to be responsible for the underlying 
mechanisms of E. histolytica trophozoites migration (de la Cruz et al., 2014). They 
have identified 16 differentially expressed proteins, of which four up-regulated 
proteins were involved in cytoskeleton organisation and cell migration. They 
observed that the overexpression of EhPC4 induced a significant increase in the 
trophozoite migration and the destruction of human SW480 colon cells. Hence, these 
proteins play an important role in the virulence of E. histolytica.  
Many E. histolytica proteins play important roles in the parasite’s 
pathogenesis, either by direct involvement or by important intracellular process. The 
PI3K family of intracellular signalling enzymes play a role in the early stages of 
phagosome formation (Powell et al., 2006, Nakada‐Tsukui et al., 2009). Further 




(Rodrı́guez et al., 2000, Okada et al., 2006, Hernandes-Alejandro et al., 2013). These 
studies indicated that many protein members of the E. histolytica proteome is 
required for amoebic trogocytosis and phagocytosis to occur. In addition, the GTPase 
families include the Rab proteins, such as EhRab7A, EhRabA and EhRabB are 
localised at the phagocytic cup and may be part of the E. histolytica secreted proteins 
(Ralston, 2015). 
 
2.2.1 Excretory-secretory proteins 
During infection, E. histolytica trophozoites release excretory-secretory (ES) 
proteins, which are also known as excretory-secretory antigens (ESA). ES proteins 
are involved in the invasion of trophozoites into the colonic mucosa by degrading the 
glycoside substrates and proteins of the host tissues (Keene et al., 1986, Scholze and 
Werries, 1986, Reed et al., 1993, Moncada et al., 2005). Antibodies against ES 
proteins have been detected in the sera of both symptomatic and asymptomatic 
patients who have contracted amoebiasis (Pal et al., 1996). 
The use of ES proteins as potential targets for diagnosis, treatment, and 
vaccine development for amoebiasis has been explored in previous studies (Quach et 
al., 2014, Wong et al., 2011, Saidin et al., 2014, Debnath et al., 2012). In diagnostics, 
the E. histolytica Gal/Gal-NAc lectin antigen is utilised in commercial antigen 
detection tests, i.e., the TechLab E. histolytica II ELISA (TechLab Inc). Furthermore, 
Gal/Gal-NAc lectin also showed potential as a vaccine candidate against E. 
histolytica (Quach et al., 2014). Another study on ES proteins showed the diagnostic 
potential of pyruvate phosphate dikinase (PPDK), and its recombinant form was used 




addition, auronofin was identified as an effective drug which targeted E. histolytica 
thioredoxin reductase (Debnath et al., 2012).  
Proteome analysis on the ES proteins of Trypanosome sp. has uncovered a 
range of proteins which include unfolding and degradation classes of proteins, such 
as serine, cysteine proteases, and metallopeptidases (Nten et al., 2009). These 
proteases play a part in the physiological and pathological functions that favour the 
invasion of the parasite, growth in hostile host conditions, evasion of components of 
the host immune defence, and hydrolysis of host proteins.  
E. histolytica secretome comprises a spectrum of proteins that may be needed 
for every facet of the parasite’s life cycle including cell modulation that is due to the 
environmental adaptation and the evasion of host’s immune responses. Hence, 
proteome studies of ES proteins may open paths to initiate novel strategies for the 
management and prevention of amoebiasis (Ahn et al., 2018). 
 
2.2.2 Membrane proteins 
Membrane proteins are important in many processes ranging from basic cellular 
process to self-defence and disease-causing processes (Santoni et al., 2000). Many of 
them are also potentially good drug targets, with an estimation of more than half of 
all drugs that have been developed targets the membrane proteins (Klabunde and 
Hessler, 2002). During E. histolytica infection, the parasite’s membrane proteins are 
used for tissue invasion, as well as the establishment of intra and extra-intestinal 




consisted of 693 proteins, whereby 87% of the identified proteins were estimated to 
be localised on the membrane surface. 
Perdomo et al. (2015) identified more than 1500 E. histolytica 
endomembrane proteins. The top two classes of proteins were involved in trafficking 
machinery and GTPases proteins with 152 and 131 proteins, respectively. The 
analysis revealed a high abundance of proteins that were involved in the intracellular 
trafficking mechanism. The most abundant protein was calreticulin, which resided at 
the endoplasmic reticulum and functioned as a calcium-buffer and a chaperone. It 
was localised at the plasma membrane and it was involved in the host cell interaction 
and the formation of phagocytic cups (Short et al., 2005). 
The membrane proteome is a landfill for the exploitation of biomarkers. In a 
proteome analysis by Che et al. (2011), over two thousand Toxoplasma gondii 
membrane proteins were identified. Over 40% of the identified membrane proteins 
were hypothetical. Furthermore, many of the membrane proteins identified were 
unique to T. gondii. Hence, the study provided a set of proteins that are suitable for 
further experimental investigation. 
The importance of identifying and studying membrane proteins is highlighted 
by the fact that they account for 70–80% of all drug targets. In addition, it is 
estimated that the majority of future drug targets are the membrane proteins 
(Hopkins et al., 2006, Overington et al., 2006). Therefore, the study of membrane 
protein in E. histolytica may even precede over ES proteins in search of potential 
novel biomarkers for drug targets. However, the detection of membrane proteins by 
standard proteomic methods is challenging due to the low abundance of membrane 




(Santoni et al., 2000, Wallin and Heijne, 1998). Therefore, it is important to establish 
a protocol for isolation of membrane proteins prior to mass spectrometry analysis. 
 
2.3 Tools for proteome discovery 
2.3.1 Sample preparation 
In-gel and in-solution digestions are the two common approaches in a bottom-up 
proteomic sample preparation (Figure 2.4). However, in the context of a complex 
protein sample, in-solution digestion requires a post peptide separation while in-gel 
digestion is already the result of pre-protein separation (Gundry et al., 2010).  
In-gel digestion followed by a mass spectrometry analysis are widely used 
techniques to identify proteins (Lasonder et al., 2002, Nten et al., 2009, Pomastowski 
and Buszewski, 2014). Before protein digestion, separation of the protein is 
performed using sodium dodecyl sulfate in a polyacrylamide gel (SDS-PAGE). 
Then, individual protein band or spot can be cored out to proceed with in-gel 
digestion. Also, depending on the complexity of the sample, several strategies are 
required for an efficient mass spectrometry analysis. This includes the need to 
consider the application of either one or two-dimensional gel electrophoresis (2-DE) 
(Pomastowski and Buszewski, 2014).  
In-solution digestion followed by mass spectrometry is one of the simplest 
and commonly used techniques (de Souza et al., 2006, Biller et al., 2014, Perdomo et 
al., 2015). This technique involves denaturing, reducing, alkylating, and digesting the 
protein sample in the liquid phase. The fractionation is usually performed after the 




different forms of chromatography tools, including, reverse-phase, strong and weak 
ion exchange, as well as size exclusion chromatography (Mostovenko et al., 2013).  
The in-gel digestion has several advantages over the in-solution digestion. In this 
method, sample complexity can be reduced without using liquid chromatography 
(LC). On the other hand, the in-solution digestion method requires fractionation 
using LC after the sample digestion step. Hence, as increased sample complexity and 
the efficiency of protein identification require longer mass spectrometry time, cost-
benefit may favour gel-based mass spectrometry compared to in-solution digestion 
(Rabilloud and Lelong, 2011). The in-solution digestion has its own advantages such 
that it is simple and straightforward to perform. Furthermore, the sample recovery of 
in-gel digestion is estimated to be 70 – 80% of the in-solution efficiency 
(Shevchenko et al., 2006, Gundry et al., 2010). In addition, the protein sample 
concentration and amount for in-solution digestion are fixed and hence the protein 
quantity can be controlled. However, for in-gel digestion, the amount of proteins 
digested from the gel is difficult to ascertain, though the amount of the initial protein 
load can be controlled (Zhou et al., 2005). 
